Clin Physiol Funct Imaging
January 2025
Background: Delayed onset muscle soreness (DOMS) is a well-established phenomenon characterized by ultrastructural muscle damage that typically develops following unfamiliar or high-intensity exercise. DOMS manifests with a constellation of symptoms, including muscle tenderness, stiffness, edema, mechanical hyperalgesia, and a reduced range of joint motion. In recent years, the application of blood flow restriction (BFR) has garnered attention for its potential impact on DOMS.
View Article and Find Full Text PDFN-nitrosodimethylamine (NDMA) was determined using a molecularly imprinted polymer (MIP)-based electrochemical sensor. Green-synthesized silver nanoparticles were functionalized with cysteamine to enhance their integration into the electrode surface, which was used to modify a glassy carbon electrode (GCE). Furthermore, a MIP-based electrochemical sensor was constructed via electropolymerization of 3-aminophenyl boronic acid (3-APBA) as a conjugated functional monomer in the presence of lithium perchlorate (LiClO) solution as a dopant, chitosan as a carrier natural polymer, and NDMA as a template/target molecule.
View Article and Find Full Text PDFBackground: Spinal cord injury (SCI) detrimentally impacts individuals' exercise capacity and respiratory parameters depending on sensory, motor, and autonomic dysfunctions. Regular physical activity (PA) positively impacts cardiovascular health and pulmonary function in these individuals. This study determined the relationship between PA and exercise capacity and respiratory parameters in individuals with SCI.
View Article and Find Full Text PDFThis work represents the first successful application of a molecularly imprinted polymer (MIP)-based electrochemical sensor for the sensitive and selective determination of the first developed proteasome inhibitor, bortezomib (BOR). BOR is used for the treatment of multiple myeloma, gastrointestinal stromal tumors, and mantle cell lymphoma. It shows its desired effect through the boronate group and can be administered intravenously or subcutaneously.
View Article and Find Full Text PDFUpadacitinib (UPA) is a selective and reversible oral Janus kinase (JAK) 1 inhibitor and is of great importance in treating inflammatory bowel disease (Zheng et al., Int Immunopharmacol 126:111229, 2024; Foy et al., JAAD Case Rep 42:20-22, 2023).
View Article and Find Full Text PDF